Increase in magnesium plasma level after orally administered trimagnesium dicitrate

Area of Science:

• Pharmacokinetics and Metabolism
• Human Physiology
• Nutritional Science

Background:

• Magnesium is essential for numerous physiological processes.
• Understanding magnesium bioavailability from different preparations is crucial for therapeutic applications.
• Plasma magnesium concentrations exhibit diurnal variations.

Purpose of the Study:

• To investigate the impact of oral and intravenous trimagnesium dicitrate on plasma magnesium levels.
• To characterize the pharmacokinetic profile of trimagnesium dicitrate.
• To provide insights into the relative bioavailability of magnesium preparations.

Main Methods:

• Healthy participants received varying doses of trimagnesium dicitrate via oral and intravenous routes.
• Plasma magnesium concentrations were monitored over time.
• Pharmacokinetic analysis, including area under the curve (AUC) and terminal half-time, was performed.

Main Results:

• Oral administration of 12 and 24 mmol magnesium led to sustained increases in plasma magnesium (3.1% and 4.6% AUC, respectively).
• Intravenous administration of 4 and 8 mmol magnesium resulted in significantly higher AUC increases (9.5% and 16.1%, respectively).
• The decline of plasma magnesium after IV administration followed a three-compartment model with an approximate 8-hour terminal half-life.

Conclusions:

• Intravenous trimagnesium dicitrate yields a more pronounced and rapid elevation in plasma magnesium compared to oral administration.
• The study provides data to help elucidate the influence of magnesium preparations on plasma concentrations.
• Further studies comparing different magnesium formulations can estimate relative oral bioavailability and bioequivalence.